Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report by Wilgucki, Molly, DO, Yeung, Vincent, MD, Ho, Grace, MD, Bravo Montenegro, Gabriela L., MD, Jones, Greg, Reuss, Joshua E., MD, Liu, Stephen V., MD, Kim, Chul, MD, MPH

Get full text